Skip to main content
. 2020 May 25;20:206. doi: 10.1186/s12886-020-01468-z

Fig. 4.

Fig. 4

Proportion of patients with a BCVA ≥70 letters by IVT-AFL regimen. Observed analysis. Regular treatment interval cohort: n = 102 (month 0); n = 102 (month 12); n = 70 (month 24). Irregular treatment interval cohort with initial doses: n = 268 (month 0); n = 268 (month 12); n = 142 (month 24). Irregular treatment interval cohort without initial doses: n = 60 (month 0); n = 60 (month 12); n = 40 (month 24). BCVA best corrected visual acuity, IVT-AFL intravitreal aflibercept